[go: up one dir, main page]

MX2009006315A - Compuesto heterociclico fusionado. - Google Patents

Compuesto heterociclico fusionado.

Info

Publication number
MX2009006315A
MX2009006315A MX2009006315A MX2009006315A MX2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A MX 2009006315 A MX2009006315 A MX 2009006315A
Authority
MX
Mexico
Prior art keywords
optionally substituted
ring
atom
bonded
heterocyclic compound
Prior art date
Application number
MX2009006315A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Hiroshi Banno
Youichi Kawakita
Tomohiro Ohashi
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2009006315A publication Critical patent/MX2009006315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe un compuesto heterocíclico fusionado que tiene actividad inhibidora de quinasa de tirosina. La fórmula (I) en la fórmula, R1 representa un átomo de hidrógeno, un átomo de halógeno, o un grupo opcionalmente sustituido el cual es unido a través de un átomo de carbono, un átomo de nitrógeno o un átomo de oxígeno, R2 representa un átomo de hidrógeno o un grupo opcionalmente sustituido el cual está unido a través de un átomo de carbono o un átomo de azufre, o como alternativa R1 y R2 o R2 y R3 son unidos respectivamente juntos para formar una estructura de anillo opcionalmente sustituido; R3 representa un átomo de hidrógeno o un grupo hidrocarburo alifático opcionalmente sustituido o alternativamente R2 está unido con un átomo de carbono del anillo A para formar una estructura de anillo opcionalmente sustituido; y el anillo A representa un anillo de benceno opcionalmente sustituido; y el anillo B representa (i) un anillo fusionado, o (u) un anillo de piridina que tiene un carbamoilo opcionalmente sustituido (en donde el anillo de piridina puede ser substituido en forma adicional).
MX2009006315A 2006-12-12 2007-12-11 Compuesto heterociclico fusionado. MX2009006315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006335158 2006-12-12
PCT/JP2007/073879 WO2008072634A1 (ja) 2006-12-12 2007-12-11 縮合複素環化合物

Publications (1)

Publication Number Publication Date
MX2009006315A true MX2009006315A (es) 2009-10-13

Family

ID=39511655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006315A MX2009006315A (es) 2006-12-12 2007-12-11 Compuesto heterociclico fusionado.

Country Status (13)

Country Link
US (1) US20100004238A1 (es)
EP (1) EP2103620A1 (es)
JP (1) JPWO2008072634A1 (es)
KR (1) KR20090090336A (es)
CN (1) CN101611041A (es)
AR (1) AR066962A1 (es)
BR (1) BRPI0720169A2 (es)
CA (1) CA2673097A1 (es)
MX (1) MX2009006315A (es)
PE (1) PE20091243A1 (es)
RU (1) RU2009126576A (es)
TW (1) TW200925160A (es)
WO (1) WO2008072634A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31704A (es) * 2008-03-12 2009-11-10 Takeda Pharmaceutical Compuesto heterociclico fusionado
JP6612751B2 (ja) * 2013-07-31 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015057A2 (pt) * 2013-12-26 2017-08-08 Ignyta Inc Compostos e composições farmacêuticas e respectivos usos
CN104876941B (zh) * 2014-02-28 2019-02-01 南京汇诚制药有限公司 稠合三环类化合物及其应用
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105924389A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 瑞戈非尼中间体的制备方法
CN105837453A (zh) * 2016-03-31 2016-08-10 常州大学 一种3,5-二氯-4’-硝基二苯醚的合成方法
CN112105618B (zh) * 2018-05-08 2022-05-31 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
JP7546550B2 (ja) * 2018-09-18 2024-09-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗腫瘍剤としてのキナゾリン誘導体
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
CA3163338A1 (en) * 2019-12-04 2021-06-10 Arcus Biosciences, Inc. Inhibitors of hif-2alpha
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
EP0922099B1 (en) 1996-07-19 2004-09-08 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
WO2001098277A2 (en) 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
NZ522989A (en) 2000-06-30 2005-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
EP1456199A1 (en) 2001-12-12 2004-09-15 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
JP4181502B2 (ja) 2001-12-12 2008-11-19 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するためのキナゾリン誘導体
US20050009845A1 (en) 2001-12-19 2005-01-13 Caferro Thomas R. Thienopyrimidine compounds as protein tyrosine kinase inhibitors
DE60237425D1 (de) 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
GEP20105024B (en) * 2004-06-02 2010-06-25 Takeda Pharmaceuticals Co Fused heterocyclic compound
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound

Also Published As

Publication number Publication date
KR20090090336A (ko) 2009-08-25
JPWO2008072634A1 (ja) 2010-04-02
RU2009126576A (ru) 2011-01-20
EP2103620A1 (en) 2009-09-23
AR066962A1 (es) 2009-09-23
PE20091243A1 (es) 2009-09-07
CA2673097A1 (en) 2008-06-19
TW200925160A (en) 2009-06-16
BRPI0720169A2 (pt) 2013-12-24
US20100004238A1 (en) 2010-01-07
WO2008072634A1 (ja) 2008-06-19
CN101611041A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
MX2009006315A (es) Compuesto heterociclico fusionado.
TW200611907A (en) Fused heterocyclic compound
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
ES2552932T3 (es) Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
PH12012501711A1 (en) [5,6] heterocyclic compound
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
EP1604665A4 (en) C-KIT KINASE HEMMER
NZ579928A (en) Fluorinated derivatives of deferiprone
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
TN2010000091A1 (en) Substituted pyrazole derivative
MXPA03005119A (es) Activadores de glucoquinasa heteroaromaticos fusionados.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
WO2009057784A1 (ja) 複素環化合物
MX2009010824A (es) Compuesto de hidrazida heterociclica y uso pesticida del mismo.
MX2010006202A (es) Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
JO3259B1 (ar) مشتق دائري مغاير ملتحم واستخدامه
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
DE602007011929D1 (de) Bohrinsel mit dreifacher aktivität
MX2009010823A (es) Compuesto de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
MY146491A (en) Fused pyrrole derivatives
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.